Power of proteomics and progress in precision medicine - 13th central and eastern European proteomic conference (CEEPC), Ustroń, Poland
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu kongresy
- Klíčová slova
- Biomarkers, cancer, clinical proteomics, exosomes, mass Spectrometry Imaging, multi-proteomics, precision medicine, socio-humanitarian, systems Biology, viral proteomics,
- MeSH
- genomika trendy MeSH
- individualizovaná medicína trendy MeSH
- lidé MeSH
- metabolomika trendy MeSH
- proteomika trendy MeSH
- software MeSH
- výpočetní biologie trendy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- kongresy MeSH
- Geografické názvy
- Polsko MeSH
INTRODUCTION: Central and Eastern European Proteomic Conference (CEEPC) provides a platform for researchers to discuss multi-disciplinary integrated approaches to address a range of challenges from present day viral pandemic to on-going progress in Precision Medicine. CEEPC brings together various multi-omics entwined with novel enabling technologies, thus facilitating conceptual advances from cell to society for the benefit of mankind. AREAS COVERED: Proteomic methodologies, databases and software has revolutionized our ability to assess protein interactions and cellular changes, allowing the establishment of biological connections and identification of important cellular regulatory proteins and pathways previously unknown or not fully understood. Additionally, Mass spectrometry (MS) remains a major driving force in the field of 'multi-omics' and a powerful technology for the structural characterization of biomolecules and for analysis of proteins and small molecules such as lipids, sugars and metabolites. Combination of measurements from proteomics, genomics, epigenomics, transcriptomics and metabolomics, present a powerful decision-making format allowing deeper interpretation of a disease scenario in Precision medicine. EXPERT COMMENTARY: Precision Medicine offers novel and promising ways to identify and treat a wide range of diseases. The future success of these therapies will be underpinned by novel proteo-genomic approaches linked to sophisticated databases to evaluate and predict drug-patient interactions.
Maria Sklodowska Curie Institute Oncology Center Gliwice Poland
Thermo Fisher Scientific Life Science Solution Carlsbad CA USA
Citace poskytuje Crossref.org